MA29465B1 - Procede d'extrusion permettant de fabriquer des compositions renfermant des composes therapeutiques peu compressibles - Google Patents

Procede d'extrusion permettant de fabriquer des compositions renfermant des composes therapeutiques peu compressibles

Info

Publication number
MA29465B1
MA29465B1 MA30393A MA30393A MA29465B1 MA 29465 B1 MA29465 B1 MA 29465B1 MA 30393 A MA30393 A MA 30393A MA 30393 A MA30393 A MA 30393A MA 29465 B1 MA29465 B1 MA 29465B1
Authority
MA
Morocco
Prior art keywords
extrusion method
therapeutic compounds
manufacturing compositions
compressible therapeutic
low compressible
Prior art date
Application number
MA30393A
Other languages
English (en)
Inventor
Madhav Vasanthavada
Jay Lakshman
Wei-Qin Tong
Abu T M Serajuddin
Yatindra Joshi
James Kowalski
Original Assignee
Novatris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novatris Ag filed Critical Novatris Ag
Publication of MA29465B1 publication Critical patent/MA29465B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UN PROCÉDÉ DE PRÉPARATION DE FORMES POSOLOGIQUES SOLIDES QUI CONTIENNENT UN COMPOSÉ THÉRAPEUTIQUE PEU COMPRESSIBLE. LE PROCÉDÉ CONCERNE PAR EXEMPLE L'UTILISATION D'UNE EXTRUDEUSE, NOTAMMENT D'UNE EXTRUDEUSE À DEUX VIS, POUR GRANULER À L'ÉTAT FONDU UN OU DES COMPOSÉ(S) THÉRAPEUTIQUE(S) À L'AIDE D'UN EXCIPIENT DE GRANULATION.
MA30393A 2005-05-10 2007-11-20 Procede d'extrusion permettant de fabriquer des compositions renfermant des composes therapeutiques peu compressibles MA29465B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67958705P 2005-05-10 2005-05-10
US69315505P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
MA29465B1 true MA29465B1 (fr) 2008-05-02

Family

ID=37022916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30393A MA29465B1 (fr) 2005-05-10 2007-11-20 Procede d'extrusion permettant de fabriquer des compositions renfermant des composes therapeutiques peu compressibles

Country Status (16)

Country Link
US (2) US20100152299A1 (fr)
EP (1) EP1881819A1 (fr)
JP (1) JP5400377B2 (fr)
KR (2) KR20130135403A (fr)
CN (1) CN102552162A (fr)
AU (2) AU2006244213B2 (fr)
BR (1) BRPI0608609A2 (fr)
CA (1) CA2607624A1 (fr)
IL (1) IL186456A0 (fr)
MA (1) MA29465B1 (fr)
MX (1) MX2007014041A (fr)
NO (1) NO20076298L (fr)
NZ (2) NZ562304A (fr)
RU (1) RU2405539C2 (fr)
TN (1) TNSN07415A1 (fr)
WO (1) WO2006122021A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
GB2447898B (en) * 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
CA2713128C (fr) 2008-01-25 2016-04-05 Gruenenthal Gmbh Forme posologique pharmaceutique
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
RU2491918C2 (ru) * 2008-07-03 2013-09-10 Новартис Аг Способ грануляции из расплава
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (fr) 2012-04-18 2018-08-22 Grünenthal GmbH Forme pharmaceutique inviolable et résistante au basculement de dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
GB201218012D0 (en) * 2012-10-08 2012-11-21 Jagotec Ag Dosage forms
EP3003279A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016170096A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Combinaison inviolable de doses fixes permettant la libération rapide de deux médicaments à partir de particules différentes
WO2016170097A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
AU2016251851A1 (en) 2015-04-24 2017-11-09 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
EP3285744A1 (fr) 2015-04-24 2018-02-28 Grünenthal GmbH Combinaison à dose fixe inaltérable présentant une libération rapide de deux médicaments de particules et d'une matrice
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
DE102018010063A1 (de) 2018-03-16 2019-09-19 Ludwig-Maximilians-Universität München Herstellung vesikulärer Phospholipid-Gele durch Schnecken-Extrusion
CN108888599B (zh) * 2018-07-26 2021-06-08 国药集团致君（深圳）制药有限公司 双氯芬酸钠缓释组合物及其制备方法
CA3203975A1 (fr) 2020-12-03 2022-06-09 Battelle Memorial Institute Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
CA3216359A1 (fr) 2021-04-07 2022-10-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
WO2023088886A1 (fr) * 2021-11-16 2023-05-25 Dsm Ip Assets B.V. Granules à haute puissance pouvant être obtenus par granulation en fusion continue
EP4432861B1 (fr) * 2021-11-16 2026-01-28 DSM IP Assets B.V. Granulé comprenant des ingrédients actifs liposolubles encapsulés
WO2023145871A1 (fr) * 2022-01-31 2023-08-03 住友精化株式会社 Procédé de fabrication de composition pour préparation pharmaceutique, et procédé de fabrication de préparation pharmaceutique
WO2023145869A1 (fr) * 2022-01-31 2023-08-03 住友精化株式会社 Procédé de fabrication de composition pour préparation pharmaceutique, et procédé de fabrication de préparation pharmaceutique
TW202412735A (zh) * 2022-08-31 2024-04-01 義大利商沙克米機械合作伊莫拉公司 製造固體藥劑的方法及裝置
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571046B1 (fr) * 1984-10-03 1987-10-16 Roquette Freres Procede de preparation de mannitol granulaire directement compressible
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19504831A1 (de) * 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose
DE19509806A1 (de) * 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
AU2000273085A1 (en) * 2000-10-02 2002-04-15 Usv Limited Sustained release pharmaceutical compositions containing metformin and method ofits production
WO2003004009A1 (fr) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Formulation a compression directe de medicaments faiblement compressibles tels que le chlorhydrate de metformine
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
IN192180B (fr) * 2001-09-28 2004-03-06 Ranbaxy Lab
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
JP2007526309A (ja) * 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
CA2626802A1 (fr) * 2005-11-09 2007-09-20 Novartis Ag Procede de fabrication de compositions pharmaceutiques utilisant un plastifiant transitoire

Also Published As

Publication number Publication date
CA2607624A1 (fr) 2006-11-16
TNSN07415A1 (en) 2009-03-17
NO20076298L (no) 2007-12-06
JP2008540540A (ja) 2008-11-20
AU2006244213B2 (en) 2010-05-13
RU2007145522A (ru) 2009-06-20
CN102552162A (zh) 2012-07-11
MX2007014041A (es) 2008-02-11
NZ562304A (en) 2010-06-25
US20100152299A1 (en) 2010-06-17
AU2010212296B2 (en) 2011-06-16
NZ585116A (en) 2011-12-22
KR20080007357A (ko) 2008-01-18
EP1881819A1 (fr) 2008-01-30
AU2010212296A1 (en) 2010-09-02
RU2405539C2 (ru) 2010-12-10
BRPI0608609A2 (pt) 2010-01-19
JP5400377B2 (ja) 2014-01-29
IL186456A0 (en) 2008-01-20
US20120077879A1 (en) 2012-03-29
KR20130135403A (ko) 2013-12-10
AU2006244213A1 (en) 2006-11-16
WO2006122021A1 (fr) 2006-11-16

Similar Documents

Publication Publication Date Title
MA29465B1 (fr) Procede d'extrusion permettant de fabriquer des compositions renfermant des composes therapeutiques peu compressibles
MA30807B1 (fr) Compositions pharmaceutiques.
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TW200722100A (en) A therapeutic agent for a β related disorders
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
MX2009001294A (es) Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
BR0213355A (pt) composições farmacêuticas
MA30070B1 (fr) Isoxazolines servant a lutter contre des animaux nuisibles invertebres
DE602006015443D1 (de) Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten
CA2449729A1 (fr) Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MA31198B1 (fr) Nouvelle forme dosifiee
WO2005023833A3 (fr) Traitement de maladies neurodegeneratives
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
MX2007006322A (es) Dihidrato de clorhidrato de (s)-(-)-1-(4-fluoroisoquinolin-5-il) sulfonil-2-metil-1,4-homopiperazina.
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
EP1972342A4 (fr) Compositions pharmaceutiques contenant un sel de tungstene (vi) utilisees dans le traitement des troubles neurodegeneratifs, en particulier la maladie d'alzheimer et la schizophrenie
MXPA03010596A (es) Preparaciones granuladas de gaboxadol.
BRPI0518786A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
MA27662A1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
EP2101742B8 (fr) Composition pharmaceutique contenant de l'hydrogénosulfate de clopidogrel de forme polymorphe 1
HRP20030885A2 (en) USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS